{
    "clinical_study": {
        "@rank": "23562", 
        "arm_group": [
            {
                "arm_group_label": "Elagolix Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Elagolix lower daily dose"
            }, 
            {
                "arm_group_label": "Elagolix Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Elagolix higher dose twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized study evaluating the continued safety and efficacy of elagolix in the\n      management of moderate to severe endometriosis associated pain in adult pre-menopausal\n      female subjects who completed 6 months treatment in Study M12-671."
        }, 
        "brief_title": "Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Endometriosis", 
        "condition_browse": {
            "mesh_term": "Endometriosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has completed the 6-Month Treatment Period in pivotal study M12-671.\n\n          -  Agrees to use required birth control methods during the study through Month 6 of the\n             Post-treatment Follow-up period\n\n        Exclusion Criteria:\n\n          -  Clinically significant gynecological condition\n\n          -  Bone mineral density (BMD) loss greater than or equal to 8 percent in the spine,\n             femoral neck or total hip\n\n          -  Plans to become pregnant in the next 18 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143713", 
            "org_study_id": "M12-821", 
            "secondary_id": "2013-001047-31"
        }, 
        "intervention": {
            "arm_group_label": [
                "Elagolix Dose 1", 
                "Elagolix Dose 2"
            ], 
            "description": "Two different doses with matching placebo (to maintain blind) daily in two different arms over a 6-Month Treatment Period", 
            "intervention_name": "Elagolix", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dysmenorrhea (DYS)", 
            "Elagolix", 
            "Non-menstrual Pelvic Pain (NMPP)", 
            "Endometriosis-associated pain", 
            "Dyspareunia", 
            "Gonadotropin-releasing Hormone Antagonist"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33176"
                    }, 
                    "name": "Site Reference ID/Investigator# 121963"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Site Reference ID/Investigator# 121939"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78258"
                    }, 
                    "name": "Site Reference ID/Investigator# 121958"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "W.Rachel  Duan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Proportion of responders based on reduction from baseline in study M12-671 (NCT 01931670)", 
                "measure": "Endometriosis-Associated Pain", 
                "safety_issue": "No", 
                "time_frame": "Month 6 of Treatment Period"
            }, 
            {
                "description": "Change from Baseline in Study M12-671 (NCT 01931670)", 
                "measure": "Bone Mineral Density (DXA scan)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 6 of Treatment Period"
            }, 
            {
                "description": "Change form Baseline in study M12-671 (NCT 01931670)", 
                "measure": "Transvaginal Ultrasound (TVU)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 6 of Treatment Period"
            }, 
            {
                "description": "Change from Baseline in Study M12-671 (NCT 01931670)", 
                "measure": "Bone Mineral Density (DXA scan)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 6 of Follow-up Period"
            }, 
            {
                "description": "Change from Baseline in Study M12-671 (NCT01931670)", 
                "measure": "Bone Mineral Density (DXA scan)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 12 of Follow-up Period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143713"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from Baseline in Study M12-671 (NCT 01931670)", 
                "measure": "Clinical Laboratory Tests (standard laboratory values including hormones)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 6 of Treatment Period"
            }, 
            {
                "measure": "Number of study subjects with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Month 18"
            }, 
            {
                "description": "Change from Baseline in Study M12-671 (NCT 01931670)", 
                "measure": "Clinical Laboratory Tests (standard laboratory values including hormones)", 
                "safety_issue": "Yes", 
                "time_frame": "Month 3 of Follow-up Period"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}